Approval · Notice of Compliance 23507 · 2020
ACT SUMATRIPTAN: Notice of Compliance 23507
Issued April 23, 2020
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 23507
- Date
- April 23, 2020
- Company
- Teva Canada LimitedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Labelling Only
- Reason
- Updated labelling materials. removal of discontiued strengths from the product monograph and merger-buyout
- Canadian reference product
- IMITREX (Glaxosmithkline Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ACT SUMATRIPTAN | 02257904 | Cancelled Post Market |
Medicinal ingredients
- SUMATRIPTAN 100 MG per TAB